David Lebovitz

Stock Analyst at Citigroup

(1)
# 1347
Out of 5,298 analysts
126
Total ratings
74.55%
Success rate
9.30%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
ALNY Alnylam Pharmaceutic...
Maintains: Strong Buy
338 351
236.07 48.68% 31 Mar 21, 2025
MDGL Madrigal Pharmaceuti...
Maintains: Strong Buy
378 469
314.29 49.23% 4 Feb 27, 2025
BMRN Biomarin Pharmaceuti...
Maintains: Neutral
81 82
60.25 36.1% 3 Feb 20, 2025
CRNX Crinetics Pharmaceut...
Maintains: Strong Buy
70 74
26.9 175.09% 2 Nov 14, 2024
MIRM Mirum Pharmaceutical...
Maintains: Strong Buy
37 38
41.97 -9.46% 1 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Sell
29 17
43.22 -60.67% 5 Oct 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
111 92
81.78 12.5% 6 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
57 54
46.98 14.94% 5 Aug 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
408 372
n/a n/a 5 May 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
11 10
n/a n/a 5 May 7, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
38 35
27.06 29.34% 6 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
16 17
1.06 1503.77% 11 Apr 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
12 11
1.34 720.9% 7 Feb 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
193 220
n/a n/a 5 Feb 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
50 500
n/a n/a 2 Dec 7, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
45 44
n/a n/a 10 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
194 199
142.83 39.33% 11 Nov 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
510 480
3.72 12803.23% 2 Nov 3, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
27 26
n/a n/a 2 Aug 13, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
119 129
n/a n/a 3 Mar 6, 2018